Kazia switches ADR depositary to JPMorgan
Kazia Therapeutics shifts its ADR depositary to JPMorgan while keeping KZIA ADS trading and holder positions unchanged.
Rhea-AI Filing Summary
Kazia Therapeutics Limited (KZIA) has appointed JPMorgan Chase Bank, N.A. as the sole depositary for its American Depositary Receipt program, replacing The Bank of New York Mellon. Under a new Second Amended and Restated Deposit Agreement, JPMorgan will issue American Depositary Shares, each representing 500 ordinary shares of Kazia.
The American Depositary Shares will continue to trade on the Nasdaq Capital Market under the symbol KZIA, and ADS holders are told they do not need to take any action. The company notes that the transition is expected to be seamless and that existing ADS positions will remain in place without interruption.
Positive
- None.
Negative
- None.
Filing Explained
The September 18 Form 6-K adds that JPMorgan filed a Form F-6 registration statement for the new ADR program and that Kazia incorporated the report into three Form F-3 registration statements; the disclosed change remains the depositary transition, with existing ADS positions continuing without interruption.
Key Figures
Ordinary shares per ADS: 500 ordinary shares per ADS
Effective date of new depositary appointment: September 18, 2026
Trading symbol: KZIA
+2 more
5 metrics
Ordinary shares per ADS
500 ordinary shares per ADS
Each American Depositary Share under the new Deposit Agreement
Effective date of new depositary appointment
September 18, 2026
Date Kazia Therapeutics appointed JPMorgan as sole depositary
Trading symbol
KZIA
ADSs continue to trade on the Nasdaq Capital Market under this symbol
Registration statement form
Form F-6
Filed by JPMorgan for the new ADR program
Incorporated Form F-3 file numbers
333-276091, 333-281937, 333-294392
Registration statements that incorporate this report by reference
Key Terms
American Depositary Receipt, American Depositary Shares, Deposit Agreement, Form F-6, +2 more
6 terms
American Depositary Receipt financial
"appointed JPMorgan Chase Bank, N.A. as the sole depositary for the Company’s American Depositary Receipt program"
An American depositary receipt (ADR) is a certificate that represents shares of a foreign company traded on U.S. stock exchanges. It allows investors to buy and sell parts of a foreign company's stock easily, much like purchasing shares of a company based in their own country. ADRs make international investing more convenient and accessible for U.S. investors.
Deposit Agreement financial
"entered into a Second Amended and Restated Deposit Agreement (the “Deposit Agreement”)"
A deposit agreement is a written contract between a customer and a financial institution that outlines the terms for opening and maintaining a deposit account, such as a savings or checking account. It explains important details like how funds can be accessed, any fees involved, and the institution’s responsibilities. For investors, understanding this agreement is important because it clarifies their rights and the rules governing their deposited funds.
Form F-6 regulatory
"JPMorgan has filed a Registration Statement on Form F-6 with the Securities and Exchange Commission"
Form F-6 is an SEC registration form used when a U.S. depositary bank creates American Depositary Receipts (ADRs), which are certificates that let U.S. investors buy and sell shares of a foreign company as if they were domestic stocks. Think of an ADR as a local-language label placed on a foreign product: it makes the foreign share easier to trade and settle in U.S. markets, increasing accessibility, liquidity and investor choice while bringing certain U.S. disclosure and regulatory oversight.
Form F-3 regulatory
"incorporates by reference the information contained herein into the Company’s registration statements on Form F-3"
Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.
Nasdaq Capital Market financial
"The ADSs will continue to trade on The Nasdaq Capital Market under the symbol “KZIA.”"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What change to the ADR program did KZIA announce in this Form 6-K?
Kazia Therapeutics appointed JPMorgan Chase Bank, N.A. as the sole depositary for its American Depositary Receipt program, replacing The Bank of New York Mellon, under a Second Amended and Restated Deposit Agreement dated September 18, 2026.
Will KZIA ADSs continue trading under the same ticker symbol after the JPMorgan appointment?
Yes. The American Depositary Shares of Kazia Therapeutics will continue to trade on the Nasdaq Capital Market under the symbol “KZIA” following the appointment of JPMorgan as the new depositary.
Do existing KZIA ADS holders need to take any action because of the new depositary?
No. The company states that ADS holders do not need to take any action at this time. The transition to JPMorgan as depositary is expected to be seamless, with holders continuing to maintain their existing ADS positions without interruption.
What SEC registration did JPMorgan file for the new KZIA ADR program?
JPMorgan Chase Bank, N.A. filed a Registration Statement on Form F-6 with the U.S. Securities and Exchange Commission in connection with Kazia Therapeutics’ new American Depositary Receipt program.
Which Kazia Therapeutics registration statements incorporate this 6-K by reference?
Kazia Therapeutics incorporates this information by reference into its Form F-3 registration statements, File Nos. 333-276091, 333-281937 and 333-294392.
AI-generated analysis. How Rhea-AI works. Not financial advice.
